Weisdorf D J, Bostrom B, Raether D, Mattingly M, Walker P, Pihlstrom B, Ferrieri P, Haake R, Goldman A, Woods W
Department of Medicine, University of Minnesota, Minneapolis 55455.
Bone Marrow Transplant. 1989 Jan;4(1):89-95.
Oral mucosal ulceration complicating bone marrow transplantation interferes with patients' comfort, nutrition and may lead to systemic infection derived from the mouth. The mucosal injury results from epithelial damage due to the cytotoxic effects of chemotherapy and radiation conditioning as well as from superficial oropharyngeal infection. Because chlorhexidine gluconate is a broad spectrum topical antimicrobial which has been demonstrably effective in preventing oral infection and gingivitis, we performed a randomized, placebo controlled, double-blind trial of chlorhexidine as a mouth rinse in BMT recipients to study the severity of oral mucositis and both oral and systemic infectious complications. One hundred patients were randomly assigned to receive either chlorhexidine gluconate 0.12% mouth rinse or placebo three times daily from the initiation (day -8) of chemoradiotherapy conditioning until day +35 post-BMT. Chlorhexidine use resulted in a trend toward improved oral hygiene index (reduced dental plaque) (p = 0.06) but did not modify the oral mucositis. Patients using chlorhexidine developed a maximum ulceration of 18 +/- 22% of their oral mucosa, while placebo patients ulcerated 25 +/- 31% of the mouth. Ulcerative mucositis was significantly worse in adults compared with children, in individuals who received methotrexate for graft-versus-host disease prophylaxis, and was most prominent on non-keratinized epithelium. Overall, there was no clinically demonstrable additional therapeutic advantage to the use of chlorhexidine in either reducing the mucositis, controlling oral pain, facilitating oral nutrition, shortening hospital stay, or reducing oral infection with herpes simplex virus. There was a trend toward diminished oral candidiasis in chlorhexidine users (p = 0.06).(ABSTRACT TRUNCATED AT 250 WORDS)
骨髓移植并发的口腔黏膜溃疡会影响患者的舒适度和营养状况,并可能导致源自口腔的全身感染。黏膜损伤是由化疗和放疗预处理的细胞毒性作用导致的上皮损伤以及口咽浅表感染引起的。由于葡萄糖酸氯己定是一种广谱局部抗菌剂,已被证明在预防口腔感染和牙龈炎方面有效,我们进行了一项随机、安慰剂对照、双盲试验,研究葡萄糖酸氯己定作为漱口液在骨髓移植受者中的应用,以探讨口腔黏膜炎的严重程度以及口腔和全身感染并发症。100名患者被随机分配,从放化疗预处理开始(第-8天)至骨髓移植后第35天,每天3次接受0.12%葡萄糖酸氯己定漱口液或安慰剂漱口。使用氯己定使口腔卫生指数有改善趋势(牙菌斑减少)(p = 0.06),但未改变口腔黏膜炎情况。使用氯己定的患者口腔黏膜最大溃疡面积为18±22%,而使用安慰剂的患者为25±31%。与儿童相比,成人的溃疡性黏膜炎明显更严重,接受甲氨蝶呤预防移植物抗宿主病的个体也是如此,且在非角化上皮处最为突出。总体而言,在减轻黏膜炎、控制口腔疼痛、促进口腔营养、缩短住院时间或减少单纯疱疹病毒口腔感染方面,使用氯己定没有临床可证实的额外治疗优势。使用氯己定的患者口腔念珠菌病有减少趋势(p = 0.06)。(摘要截短于250字)